Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Nektar Therapeutics
Nektar Therapeutics Al Corporation
Nektar Therapeutics Al Corporation_20100114
Nektar Therapeutics incorporated Under The Laws Of Delaware And Domiclled In The State Of Ca
Nektar Therapeutics india Pvt Ltd
Nektar Therapeutics india Pvt ltd
Nektar Therapeutics_20131212
Nektar Therapeutics_20100128
Nektar Therapeutics_20100107

Nektar Therapeutics patents


Recent patent applications related to Nektar Therapeutics. Nektar Therapeutics is listed as an Agent/Assignee. Note: Nektar Therapeutics may have other listings under different names/spellings. We're not affiliated with Nektar Therapeutics, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "N" | Nektar Therapeutics-related inventors


N-methyl-n-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor

Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.... Nektar Therapeutics

Oligomer-beta blocker conjugates

The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small... Nektar Therapeutics

Composition comprising a polymeric reagent

The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. The conjugates as well as the polymeric reagents used to form the conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and... Nektar Therapeutics

Compositions of particulate coformulation

Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface... Nektar Therapeutics

Methods for preparing polymeric reagents and compositions of polymeric reagents

Methods for preparing active carbonate esters of water-soluble polymers are provided. Also provided are other methods related to the active carbonate esters of water-soluble polymers, as well as corresponding compositions.... Nektar Therapeutics

Particulate materials

The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to... Nektar Therapeutics

Sealed nebulizer liquid reservoir systems and methods

Methods, systems, and devices are described for sealing a nebulizer's liquid reservoir. A nebulizer liquid reservoir may be provided that is in fluid communication with an aerosol generator. The nebulizer liquid reservoir may have an open end and a headspace. A cap may be placed on the open end of... Nektar Therapeutics

Opioid agonists and uses thereof

Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.... Nektar Therapeutics

Oligomer-foscarnet conjugates

The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds.... Nektar Therapeutics

Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof

Solid forms of certain opioid agonists are provided herein. Methods of preparing the solid forms, methods of using the solid forms, and pharmaceutical compositions comprising the solid forms are also provided herein.... Nektar Therapeutics

Conjugates of an anti-tnf-alpha antibody

Conjugates of an anti-TNF antibody and one or more nonpeptidic water-soluble polymers are provided. Typically, the nonpeptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.... Nektar Therapeutics

Multi-arm polymeric alkanoate conjugates

Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.... Nektar Therapeutics

Particulate materials

Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having... Nektar Therapeutics

N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides

The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.... Nektar Therapeutics

Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an anti-pd-1 antibody

The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2Rβ-activating amount of a long acting, IL-2Rβ-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an... Nektar Therapeutics

Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method

Provided herein are polymeric α-hydroxy aldehyde or α-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via... Nektar Therapeutics

Oligomer-opioid agonist conjugates

The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.... Nektar Therapeutics

Chemically modified small molecules

Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a... Nektar Therapeutics

N-maleimidyl polymer derivatives

The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The... Nektar Therapeutics

Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound

The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist compound and an analgesic compound, methods for administering an opioid agonist compound and an analgesic compound,... Nektar Therapeutics

Systems and methods for driving nebulizers

In various arrangements, a nebulizer element of a nebulizer may be energized with a drive signal. A phase offset of the drive signal may be measured. A phase delta may be determined. The phase delta may indicate a difference between a target phase offset and the measured phase offset. The... Nektar Therapeutics

Method for preparing functionalized polymers from polymer alcohols

The present invention provides, among other things, compounds that include a water-soluble and non-peptidic polymer as well as a maleimidyl group. The compounds are useful as, among other things, polymeric reagents.... Nektar Therapeutics

Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine

The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.... Nektar Therapeutics

Multi-arm polymer prodrugs

Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The... Nektar Therapeutics

Polymer factor ix moiety conjugates

Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the... Nektar Therapeutics

Conjugates of an il-15 moiety and a polymer

Conjugates of an IL-15 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to an individual.... Nektar Therapeutics

Protease inhibitors having enhanced features

Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.... Nektar Therapeutics

Opioid agonists and uses thereof

Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.... Nektar Therapeutics

Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an anti-pd-1 antibody

The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2Rβ-activating amount of a long acting, IL-2Rβ-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an... Nektar Therapeutics

Opioid agonists and uses thereof

Provided are compounds, including those of Formula I; and pharmaceutically acceptable salts and solvates thereof. The compounds described herein relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.... Nektar Therapeutics








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Nektar Therapeutics in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Nektar Therapeutics with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###